c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

Takumi Kumai, Yoshinari Matsuda, Takayuki Ohkuri, Kensuke Oikawa, Kei Ishibashi, Naoko Aoki, Shoji Kimura, Yasuaki Harabuchi, Esteban Celis, Hiroya Kobayashi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-β production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLADR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-β production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalOncoImmunology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

T-Cell Lymphoma
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Natural Killer Cells
Immunotherapy
T-Lymphocytes
T-Lymphocyte Epitopes
Neoplasms
Cell Proliferation
Autophagy
Nose
Dendritic Cells
Ligands
Cell Line
Peptides

Keywords

  • Autophagy
  • C-Met
  • CD4 helper T lymphocytes
  • Head and neck squamous cell carcinoma
  • Immunotherapy
  • Major histo-compatibility complex class II
  • NK/T cell lymphoma
  • TGF-β
  • Tumor antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Kumai, T., Matsuda, Y., Ohkuri, T., Oikawa, K., Ishibashi, K., Aoki, N., ... Kobayashi, H. (2015). c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. OncoImmunology, 4(2), 1-10. https://doi.org/10.4161/2162402X.2014.976077

c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. / Kumai, Takumi; Matsuda, Yoshinari; Ohkuri, Takayuki; Oikawa, Kensuke; Ishibashi, Kei; Aoki, Naoko; Kimura, Shoji; Harabuchi, Yasuaki; Celis, Esteban; Kobayashi, Hiroya.

In: OncoImmunology, Vol. 4, No. 2, 01.01.2015, p. 1-10.

Research output: Contribution to journalArticle

Kumai, T, Matsuda, Y, Ohkuri, T, Oikawa, K, Ishibashi, K, Aoki, N, Kimura, S, Harabuchi, Y, Celis, E & Kobayashi, H 2015, 'c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma', OncoImmunology, vol. 4, no. 2, pp. 1-10. https://doi.org/10.4161/2162402X.2014.976077
Kumai, Takumi ; Matsuda, Yoshinari ; Ohkuri, Takayuki ; Oikawa, Kensuke ; Ishibashi, Kei ; Aoki, Naoko ; Kimura, Shoji ; Harabuchi, Yasuaki ; Celis, Esteban ; Kobayashi, Hiroya. / c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. In: OncoImmunology. 2015 ; Vol. 4, No. 2. pp. 1-10.
@article{9b635d522b9b40039fcdd9b44007beab,
title = "c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma",
abstract = "Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-β production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLADR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-β production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.",
keywords = "Autophagy, C-Met, CD4 helper T lymphocytes, Head and neck squamous cell carcinoma, Immunotherapy, Major histo-compatibility complex class II, NK/T cell lymphoma, TGF-β, Tumor antigens",
author = "Takumi Kumai and Yoshinari Matsuda and Takayuki Ohkuri and Kensuke Oikawa and Kei Ishibashi and Naoko Aoki and Shoji Kimura and Yasuaki Harabuchi and Esteban Celis and Hiroya Kobayashi",
year = "2015",
month = "1",
day = "1",
doi = "10.4161/2162402X.2014.976077",
language = "English (US)",
volume = "4",
pages = "1--10",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

AU - Kumai, Takumi

AU - Matsuda, Yoshinari

AU - Ohkuri, Takayuki

AU - Oikawa, Kensuke

AU - Ishibashi, Kei

AU - Aoki, Naoko

AU - Kimura, Shoji

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

AU - Kobayashi, Hiroya

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-β production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLADR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-β production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.

AB - Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-β production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLADR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-β production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.

KW - Autophagy

KW - C-Met

KW - CD4 helper T lymphocytes

KW - Head and neck squamous cell carcinoma

KW - Immunotherapy

KW - Major histo-compatibility complex class II

KW - NK/T cell lymphoma

KW - TGF-β

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=84946590578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946590578&partnerID=8YFLogxK

U2 - 10.4161/2162402X.2014.976077

DO - 10.4161/2162402X.2014.976077

M3 - Article

AN - SCOPUS:84946590578

VL - 4

SP - 1

EP - 10

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 2

ER -